RG6330
metastatic solid tumors with KRAS G12C mutation
metastatic solid tumors with KRAS G12C mutation
Cancer immunotherapy is the use of the immune system to fight cancer. ERY974 is a bispecific antibody designed to elicit T cell activation and T cell-dependent cellular cytotoxicity by simultaneously binding to glypican-3, a protein expressed in certain cancers, and CD3 on the surface of T cells. A phase I clinical trial is evaluating ERY974 for the treatment of solid tumors.
Glofitamab (Anti-CD20 CD3 TCB, RG6026) is a 2:1 format T cell-engaging bispecific antibody, designed to engage both CD20 on B cells and CD3 on T cells. By engaging both targets simultaneously, the antibody activates the T cells to attack and eliminate the B cells, allowing treatment of B cell cancers such as non-Hodgkin’s lymphoma. A phase I clinical trial is evaluating RG6026 for the treatment of relapsed or refractory non-Hodgkin's lymphoma.
tiragolumab (anti-TIGIT, RG6058) is a fully human monoclonal antibody designed to bind to TIGIT and prevent its interaction with poliovirus receptor (PVR). T cell immunoglobulin and ITIM domain protein (TIGIT), a member of the immunoglobulin superfamily, is a novel immune inhibitory receptor. A phase I clinical trial is evaluating tiragolumab in combination with Tecentriq for the treatment of solid tumors.
tiragolumab (anti-TIGIT, RG6058) is a fully human monoclonal antibody designed to bind to TIGIT and prevent its interaction with poliovirus receptor (PVR). T cell immunoglobulin and ITIM domain protein (TIGIT), a member of the immunoglobulin superfamily, is a novel immune inhibitory receptor. A phase I clinical trial is evaluating tiragolumab in combination with Tecentriq for the treatment of solid tumors.
CD19-4-1BBL(RG6076) is a fusion protein targeting the 4-1BB ligand to cells bearing CD19 acting as an NK- and T-cell co-stimulator.
TLR7 agonist (4) is an oral, small molecule immuno-modulator activating the TLR (toll-like receptor) 7. It stimulates the production of cytokines and may promote an inflammatory microenvironment, fostering T-cell activation and anti-tumor immunity.
The bispecific monoclonal antibody PD1 x LAG3 (RG6139) binds to the PD-1 and LAG-3 inhibitory checkpoint receptors on the surface of T-cells. PD1 x LAG3 MAb enable preferential targeting of dysfunctional effector T-cells over regulatory T-cells mediating immunosuppressive effects while restoring anti-tumor immune response. RG6139 is currently in phase I clinical study for solid tumors.
RG6171 (GDC-9545) is a selective estrogen receptor degrader (SERD) that is designed to bind to the estrogen receptor to limit its function. In addition, when SERDs bind to the estrogen receptor, they may be able to change the shape of the receptor in such a way that the cell eliminates it by degradation. A phase I clinical trial is evaluating RG6171 for the treatment of ER-positive and HER2-negative metastatic breast cancer.
Individualized Neoantigen-Specific Therapy, iNeST (RG6180) is a messenger RNA (mRNA)-based, individually tailored, personalized cancer vaccine. Each vaccine will be made using unique neoantigen signatures from an individual patient’s tumor, which is expected to elicit an effective immune response against that patient’s tumor. A phase I clinical trial is evaluating iNeST for the treatment of solid tumors.
RG6185 (GDC-5573, HM95573) is a selective small-molecule inhibitor of the RAF family kinases designed to inhibit the MAPK pathway, which is frequently activated in human tumors and drives tumor growth. A phase I clinical trial is evaluating RG6185 for the treatment of solid tumors.
RG6194 is a bispecific antibody designed to target both the HER2-positive cells and CD3 on T cells. This dual-targeting antibody is designed to induce a polyclonal T-cell response against HER2-positive tumors. A phase I clinical trial is evaluating RG6194 for the treatment of metastatic HER2-positive cancers.
The immunocytokine PD1-IL2v is an antibody fusion protein blocking PD1 combined with an engineered interleukin-2 variant (IL2v) inducing immune-modulating activity
The trial (NCT03973333) is designed to study the safety and preliminary activity of MAGE-A4 ImmTAC as a monotherapy and in combination with atezolizumab (Tecentriq) in patients with MAGE-A4-expressing cancers.
RG6292 is a monoclonal antibody that targets CD25 (IL-2Rα). The antibody mediates the depletion of regulatory T-cells (Tregs), a major suppressor of the anti-cancer immune response. RG6292 does not interfere with IL-2 signaling of other immune cells which are acting against the tumor. A phase I clinical trial is evaluating RG6292 in solid tumors (NCT 04158583).
IL15/IL15Ra-Fc alone, and in combination with Tecentriq
Cotellic (cobimetinib, RG7421) is a selective inhibitor of MEK, also known as mitogen activated protein kinase kinase (MAPKK), a key component of the RAS/RAF/MEK/ERK pathway that is frequently activated in human tumours. Inappropriate activation of the MEK/ERK pathway promotes cell growth in the absence of exogenous growth factors. A phase I clinical trial is evaluating Cotellic in combination with Tecentriq (atezolizumab, anti-PDL1) and Avastin as a second or third line treatment in patients with advanced or metastatic colorectal cancer.
Ipatasertib (RG7440) is a small molecule pan-Akt inhibitor. The PI3K/Akt/mTOR pathway regulates cell growth and survival. A phase I clinical trial is evaluating ipatasertib with rucaparib (a small-molecule PARP inhibitor) for the treatment of metastatic castration-resistant prostate cancer and solid tumors.
Ipatasertib (RG7440) is a small molecule pan-Akt inhibitor. The PI3K/Akt/mTOR pathway regulates cell growth and survival. A phase I trial is evaluating ipatasertib in combination with Tecentriq and Taxane as a treatment in patients with TNBC.
Ipatasertib plus Tecentriq is being tested in a Phase I study in prostate cancer patients who have been previously treated with androgen receptor-targeted therapy
Cancer immunotherapy is the use of the immune system to fight cancer. Tecentriq, (atezolizumab, anti-PDL1, RG7446, MPDL3280A) is an engineered monoclonal antibody that targets the ligand PD-L1 (programmed death ligand 1) aiming to prevent cancer immune evasion. A phase Ib trial is evaluating Tecentriq in combination with rucaparib (a small-molecule PARP inhibitor) in advanced gynecologic cancers, with a focus on ovarian cancer.
Cancer immunotherapy is the use of the immune system to fight cancer. Tecentriq (atezolizumab) is an engineered monoclonal antibody that targets the ligand PD-L1 (programmed death ligand 1) aiming to prevent cancer immune evasion. A phase I trial evaluating Tecentriq in combination with Zelboraf (vemurafenib), with or without Cotellic (cobimetinib), for the treatment of metastatic melanoma is ongoing.
Cancer immunotherapy is the use of the immune system to fight cancer. Tecentriq (atezolizumab) is an engineered monoclonal antibody that targets the ligand PD-L1 (programmed death-ligand 1) aiming to prevent cancer immune evasion. A phase I clinical trial evaluating Tecentriq for the treatment of locally advanced or metastatic solid tumors is ongoing.
Cancer immunotherapy is the use of the immune system to fight cancer. Tecentriq (atezolizumab) is a monoclonal antibody that targets PD-L1 (programmed death ligand 1) aiming to prevent cancer immune evasion. MORPHEUS pancreatic cancer study is testing a number of cancer immunotherapy combinations to inform future development. MORPHEUS is a phase Ib/II adaptive development platform established by Roche to assess the efficacy and safety of combination cancer immunotherapies.
Cancer immunotherapy is the use of the immune system to fight cancer. Tecentriq (atezolizumab, anti-PDL1, RG7446, MPDL3280A) is an engineered monoclonal antibody that targets the ligand PD-L1 (programmed death ligand 1) aiming to prevent cancer immune evasion. A phase Ib trial is evaluating Tecentriq in combination with Kadcyla (trastuzumab emtansine) or with Herceptin (trastuzumab) and Perjeta (pertuzumab), with or without chemotherapy, as appropriate, in patients with HER2-positive breast cancer.
Cancer immunotherapy is the use of the immune system to fight cancer. Tecentriq, (atezolizumab, anti-PDL1, RG7446, MPDL3280A) is an engineered monoclonal antibody that targets the ligand PD-L1 (programmed death ligand 1) aiming to prevent cancer immune evasion. A phase I trial is evaluating Tecentriq in combination with anti-CD47 MAb in relapsed or refractory AML.
Tecentriq plus Venclexta in the treatment of 1L extensive stage-small cell lung cancer in the maintenance setting
RG7461 is a targeted immunocytokine combining an engineered interleukin-2 variant (IL2v) with an antibody against fibroblast activation protein (FAP), a protein expressed in several cancers. A phase I clinical trial evaluating RG7461 in solid tumors is ongoing.
Venclexta (venetoclax, RG7601) is a novel small molecule Bcl-2 selective inhibitor designed to restore apoptosis, also known as programmed cell death, by blocking the function of a pro-survival Bcl-2 family protein. The Bcl-2 family proteins, which are expressed at high levels in many tumors, play a central role in regulating apoptosis and, consequently, are thought to impact tumor formation, tumor growth, and resistance. A phase I clinical trial is evaluating Venclexta for the treatment of relapsed or refractory chronic lymphocytic leukemia.
Venclexta (venetoclax, RG7601) is a small molecule Bcl-2 selective inhibitor designed to restore apoptosis, also known as programmed cell death, by blocking the function of a pro-survival Bcl-2 family protein. Gazyva, (obinutuzumab), is the first glycoengineered, type II, humanized anti-CD20 monoclonal antibody specifically designed to selectively target the CD20 protein on malignant B-cells and to bind with high affinity to the cell surface in a type II configuration. a phase I clinical trial is evaluating Venclexta in combination with Gazyva for the treatment of chronic lymphocytic leukemia.
Venclexta (venetoclax, RG7601) is a novel small molecule Bcl-2 selective inhibitor designed to restore apoptosis, also known as programmed cell death, by blocking the function of a pro-survival Bcl-2 family protein. The Bcl-2 family proteins, which are expressed at high levels in many tumors, play a central role in regulating apoptosis and, consequently, are thought to impact tumor formation, tumor growth and resistance. A phase I clinical trial is evaluating Venclexta in combination with the gilteritinib for the treatment of patients with relapsed or refractory acute myeloid leukemia.
Venclexta (venetoclax, RG7601) is a novel small molecule Bcl-2 selective inhibitor designed to restore apoptosis, also known as programmed cell death, by blocking the function of a pro-survival Bcl-2 family protein. The Bcl-2 family proteins, which are expressed at high levels in many tumors, play a central role in regulating apoptosis and, consequently, are thought to impact tumor formation, tumor growth, and resistance. A phase I clinical trial is evaluating Venclexta as a single agent and in combination with the hypomethylating agent azacitidine in patients with relapsed or refractory myelodysplastic syndromes.
Venclexta (venetoclax, RG7601) is a novel small molecule Bcl-2 selective inhibitor designed to restore apoptosis, also known as programmed cell death, by blocking the function of a pro-survival Bcl-2 family protein. The Bcl-2 family proteins, which are expressed at high levels in many tumors, play a central role in regulating apoptosis and, consequently, are thought to impact tumor formation, tumor growth, and resistance. A phase I clinical trial is investigating Venclexta in combination with AMG176 (Amgen) for the treatment of relapsed or refractory acute myeloid leukemia.
RG7769 ( PD1-TIM3) is a bispecific antibody that binds to two co-inhibitory checkpoint receptors, PD-1 and TIM-3, to reinvigorate dysfunctional T-cells enabling them to attack the tumor. A phase I clinical trial is evaluating RG7769 for the treatment of solid tumors.
cibisatamab (RG7802) is a bispecific antibody designed to simultaneously target carcinoembryonic antigen (CEA) expressed on tumor cells and the CD3 receptor present on T cells, triggering T cell activation, migration and tumor killing. A phase I clinical trial is evaluating cibisatamab for the treatment of CEA-expressing solid tumors, as a single agent and in combination with atezolizumab.
RG7827 (FAP 4-1BBL FP) is an agonistic immune modulator and targeted T-cell co-stimulator, which inhibits tumor growth by activating tumor-specific T-cells. RG7827 has an antibody-like structure, with one arm binding to FAP, which is a protein found in the stroma of many solid tumor types, and the other arm carrying the signaling molecule, 4-1BBL. A phase I clinical trial is evaluating RG7827 for the treatment of solid tumors.
mosunetuzumab (Anti-CD20/CD3 TDB, RG7828) is a humanized full-length T cell-dependent bispecific antibody designed to target both CD20 on B cells and CD3 on T cells. This dual-targeting antibody is designed to redirect T cells to attack cancer cells. A phase I clinical trial is evaluating mosunetuzumab for the treatment of hematologic tumors.
Selicrelumab (RG7876) is a fully human (IgG2) agonistic antibody against CD40. The antibody induces T cell-driven tumor killing by activation of CD40 on antigen-presenting cells which in turn prime T cells to attack the tumor. A phase I clinical trial is evaluating selicrelumab in combination with vanucizumab or Avastin for the treatment of solid tumors.
SQZ-PBMC-HPV as Monotherapy and in Combination With Atezolizumab
Randomised Phase II (SKYSCRAPER-04) in metastatic and/or recurrent PD-L1+ cervical cancer in combination with Tecentriq. tiragolumab (anti-TIGIT, RG6058) is a fully human monoclonal antibody designed to bind to TIGIT and prevent its interaction with poliovirus receptor (PVR). T cell immunoglobulin and ITIM domain protein (TIGIT), a member of the immunoglobulin superfamily, is a novel immune inhibitory receptor.
RG6171 (GDC-9545) is a selective estrogen receptor degrader (SERD) that is designed to bind to the estrogen receptor to limit its function. In addition, when SERDs bind to the estrogen receptor, they may be able to change the shape of the receptor in such a way that the cell eliminates it by degradation.
Individualised Neoantigen-Specific Therapy, iNeST (RG6180) is a messenger RNA (mRNA)-based, individually tailored, personalized cancer vaccine. Each vaccine will be made using unique neoantigen signatures from an individual patient’s tumor, which is expected to elicit an effective immune response against that patient’s tumor. A phase II clinical trial is evaluating iNeST for the treatment of first line melanoma.
Cancer immunotherapy is the use of the immune system to fight cancer. Tecentriq (atezolizumab) is an engineered monoclonal antibody that targets the ligand PD-L1 (programmed death-ligand 1) aiming to prevent cancer immune evasion. A phase II is evaluating atezolizumab subcutaneous (SC) followed by atezolizumab IV for the treatment of locally advanced or metastatic non-small cell lung cancer.
Venclexta (venetoclax, RG7601) is a novel small molecule Bcl-2 selective inhibitor designed to restore apoptosis, also known as programmed cell death, by blocking the function of a pro-survival Bcl-2 family protein. A phase II clinical trial is evaluating Venclexta in combination with the carfilzomib and dexamethasone for the treatment of patients with relapsed or refractory acute myeloid leukemia.
Venclexta (venetoclax, RG7601, GDC-0199, ABT-199) is a novel small molecule Bcl-2 selective inhibitor designed to restore apoptosis, also known as programmed cell death, by blocking the function of a pro-survival Bcl-2 family protein. The Bcl-2 family proteins, which are expressed at high levels in many tumors, play a central role in regulating apoptosis and, consequently, are thought to impact tumor formation, tumor growth, and resistance. A phase II clinical trial is evaluating ipatasertib for the treatment of second line or later HR-positive breast cancer.
Randomised Phase III (SKYSCRAPER-02) of tiragolumab plus Tecentriq in 1L non-small cell lung cancer (NSCLC) patients whose tumours express PD-L1 (TPS>50%). tiragolumab (anti-TIGIT, RG6058) is a fully human monoclonal antibody designed to bind to TIGIT and prevent its interaction with poliovirus receptor (PVR). T cell immunoglobulin and ITIM domain protein (TIGIT), a member of the immunoglobulin superfamily, is a novel immune inhibitory receptor.
Randomised Phase III (SKYSCRAPER-02) of tiragolumab plus Tecentriq in 1L small cell lung cancer (SCLC). tiragolumab (anti-TIGIT, RG6058) is a fully human monoclonal antibody designed to bind to TIGIT and prevent its interaction with poliovirus receptor (PVR). T cell immunoglobulin and ITIM domain protein (TIGIT), a member of the immunoglobulin superfamily, is a novel immune inhibitory receptor.
Randomised Phase III (SKYSCRAPER-02) of tiragolumab plus Tecentriq in 1L non-small cell lung cancer (NSCLC) patients whose tumours express PD-L1 (TPS>50%). tiragolumab (anti-TIGIT, RG6058) is a fully human monoclonal antibody designed to bind to TIGIT and prevent its interaction with poliovirus receptor (PVR). T cell immunoglobulin and ITIM domain protein (TIGIT), a member of the immunoglobulin superfamily, is a novel immune inhibitory receptor.
Randomised Phase III (SKYSCRAPER-02) of tiragolumab plus Tecentriq in 1L non-small cell lung cancer (NSCLC) patients whose tumours express PD-L1 (TPS>50%). tiragolumab (anti-TIGIT, RG6058) is a fully human monoclonal antibody designed to bind to TIGIT and prevent its interaction with poliovirus receptor (PVR). T cell immunoglobulin and ITIM domain protein (TIGIT), a member of the immunoglobulin superfamily, is a novel immune inhibitory receptor.
RG6114 (GDC-0077) is a small molecule PI3 kinase (PI3K) inhibitor. Dysregulation of PI3K signaling is implicated in a broad range of human cancers, and activating mutations in the PI3K alpha-isoform gene (PIK3CA) are common oncogenic drivers. The PI3K/Akt/mTOR pathway regulates cell growth and survival.
RG6171 (GDC-9545) is a selective estrogen receptor degrader (SERD) that is designed to bind to the estrogen receptor to limit its function. In addition, when SERDs bind to the estrogen receptor, they may be able to change the shape of the receptor in such a way that the cell eliminates it by degradation.
Ipatasertib (RG7440) is a small molecule pan-Akt inhibitor. The PI3K/Akt/mTOR pathway regulates cell growth and survival. A phase III clinical trial is evaluating ipatasertib for the treatment of first line castration-resistant prostate cancer.
Ipatasertib (RG7440) is a small molecule pan-Akt inhibitor. The PI3K/Akt/mTOR pathway regulates cell growth and survival. A phase III clinical trial is evaluating ipatasertib for the treatment of first line triple-negative and HR-positive breast cancer.
Ipatasertib (RG7440) is a small molecule pan-Akt inhibitor. The PI3K/Akt/mTOR pathway regulates cell growth and survival. A phase III clinical trial is evaluating ipatasertib in combination with palbociclib and fulvestrant for the treatment of HR-positive metastatic breast cancer.
Ipatasertib (RG7440) is a small molecule pan-Akt inhibitor. The PI3K/Akt/mTOR pathway regulates cell growth and survival. A phase III clinical trial is evaluating ipatasertib in combination with Tecentriq and paclitaxel for the treatment of first line triple-negative breast cancer.
Cancer immunotherapy is the use of the immune system to fight cancer. Tecentriq (anti-PDL1, RG7446, atezolizumab) is an engineered monoclonal antibody that targets the ligand PD-L1 (programmed death ligand 1) aiming to prevent cancer immune evasion. Tecentriq is being evaluated in a phase II/III clinical trial for non-squamous non-small cell lung cancer patients who are positive via blood based tumor mutational burden(TMB) assay.
Cancer immunotherapy is the use of the immune system to fight cancer. Tecentriq, (atezolizumab, anti-PDL1, RG7446, MPDL3280A) is an engineered monoclonal antibody that targets the ligand PD-L1 (programmed death ligand 1) aiming to prevent cancer immune evasion. A phase III trial is evaluating Tecentriq in combination with chemotherapy or as monotherapy in patients with locally advanced or metastatic urothelial carcinoma who have not received prior systemic therapy.
Cancer immunotherapy is the use of the immune system to fight cancer. Tecentriq (atezolizumab, anti-PDL1, RG7446, MPDL3280A) is an engineered monoclonal antibody that targets the ligand PD-L1 (programmed death ligand 1) aiming to prevent cancer immune evasion. A phase III clinical trial is investigating Tecentriq in combination with nab-paclitaxel (Abraxane) as a potential neoadjuvant (before surgery) treatment for triple-negative breast cancer.
Cancer immunotherapy is the use of the immune system to fight cancer. Tecentriq (anti-PDL1, RG7446, Atezolizumab ) is an engineered monoclonal antibody that targets the ligand PD-L1 (programmed death ligand 1) aiming to prevent cancer immune evasion. Tecentriq is being evaluated in a phase III clinical trial as a potential adjuvant treatment, following surgery and adjuvant cisplatin-based chemotherapy, for patients with non-small cell lung cancer whose tumors express PDL1.
Cancer immunotherapy is the use of the immune system to fight cancer. Tecentriq, (atezolizumab, anti-PDL1, RG7446, MPDL3280A) is an engineered monoclonal antibody that targets the ligand PD-L1 (programmed death ligand 1) aiming to prevent cancer immune evasion. A phase III trial is evaluating Tecentriq in patients with adjuvant squamous cell carcinoma of the head and neck (SCCHN).
Cancer immunotherapy is the use of the immune system to fight cancer. Tecentriq (atezolizumab, RG7446) is an engineered monoclonal antibody that targets the ligand PD-L1 (programmed death ligand 1) aiming to prevent cancer immune evasion. A phase III trial is evaluating ddAC Trastuzumab/Pertuzumab + chemotherapy + Tecentriq followed by surgery and chemotherapy +Tecentriq in the treatment of neoadjuvant HER2+ breast cancer.
Cancer immunotherapy is the use of the immune system to fight cancer. Tecentriq (atezolizumab, anti-PDL1, RG7446, MPDL3280A) is an engineered monoclonal antibody that targets the ligand PD-L1 (programmed death ligand 1) aiming to prevent cancer immune evasion. A phase III trial is evaluating Tecentriq in combination with Avastin in adjuvant Hepatocellular carcinoma (HCC)
Cancer immunotherapy is the use of the immune system to fight cancer. Tecentriq (anti-PDL1, RG7446, Atezolizumab) is an engineered monoclonal antibody that targets the ligand PD-L1 (programmed death ligand 1) aiming to prevent cancer immune evasion. Tecentriq is being evaluated in a phase III clinical trial as a potential adjuvant treatment, in combination with paclitaxel, for triple-negative breast cancer.
Cancer immunotherapy is the use of the immune system to fight cancer. Tecentriq (anti-PDL1, RG7446, atezolizumab) is an engineered monoclonal antibody that targets the ligand PD-L1 (programmed death ligand 1) aiming to prevent cancer immune evasion. Tecentriq is being evaluated in a phase III clinical trial as a potential first-line treatment, in combination with capecitabine or carboplatin/gemcitabine, for metastatic triple-negative breast cancer.
Cancer immunotherapy is the use of the immune system to fight cancer. Tecentriq, (atezolizumab, anti-PDL1, RG7446, MPDL3280A) is an engineered monoclonal antibody that targets the ligand PD-L1 (programmed death ligand 1) aiming to prevent cancer immune evasion. A phase III clinical trial is evaluating Tecentriq for the treatment of adjuvant renal cell carcinoma.
Cancer immunotherapy is the use of the immune system to fight cancer. Tecentriq (anti-PDL1, RG7446, atezolizumab) is an engineered monoclonal antibody that targets the ligand PD-L1 (programmed death ligand 1) aiming to prevent cancer immune evasion. A phase III trial is evaluating Tecentriq in combination with cabozantinib for the treatment of advanced renal cell carcinoma after immune checkpoint inhibitor treatment
Cancer immunotherapy is the use of the immune system to fight cancer. Tecentriq (anti-PDL1, RG7446, atezolizumab) is an engineered monoclonal antibody that targets the ligand PD-L1 (programmed death ligand 1) aiming to prevent cancer immune evasion. A phase III trial is evaluating Tecentriq in combination with cabozantinib for the treatment of 2L non small cell lung cancer (NSCLC)
Polivy (Polatuzumab vedotin) is an antibody-drug conjugate (ADC) that consists of a monoclonal antibody anti-CD79b, conjugated to a potent anti-cancer agent that is selectively delivered to tumor cells. A phase III clinical trial is evaluating Polivy for the treatment of first line diffuse large B-cell lymphoma.
Venclexta (venetoclax, RG7601, GDC-0199, ABT-199) is a novel small molecule Bcl-2 selective inhibitor designed to restore apoptosis, also known as programmed cell death, by blocking the function of a pro-survival Bcl-2 family protein. The Bcl-2 family proteins, which are expressed at high levels in many tumors, play a central role in regulating apoptosis and, consequently, are thought to impact tumor formation, tumor growth and resistance. A phase III clinical trial is evaluating Venclexta for the treatment of relapsed or refractory t(11;14)-positive multiple myeloma.
Venclexta (venetoclax, RG7601) is a novel small molecule Bcl-2 selective inhibitor designed to restore apoptosis, also known as programmed cell death, by blocking the function of a pro-survival Bcl-2 family protein. The Bcl-2 family proteins, which are expressed at high levels in many tumors, play a central role in regulating apoptosis and, consequently, are thought to impact tumor formation, tumor growth, and resistance.
Alecensa (Alectinib, RG7853) is a small molecule designed to selectively target ALK (anaplastic lymphoma kinase) and to penetrate and stay in the central nervous system. Alectinib binds ALK, inhibiting downstream malignant pathways that contribute to tumorigenesis and disease progression. A phase III clinical trial is evaluating Alecensa for the treatment of adjuvant ALK-positive non-small cell lung cancer.
Venclexta (venetoclax, RG7601) is a novel small molecule Bcl-2 selective inhibitor designed to restore apoptosis, also known as programmed cell death, by blocking the function of a pro-survival Bcl-2 family protein. The Bcl-2 family proteins, which are expressed at high levels in many tumors, play a central role in regulating apoptosis and, consequently, are thought to impact tumor formation, tumor growth, and resistance. A phase III clinical trial is evaluating Venclexta in combination with the hypomethylating agent azacitidine for the treatment of patients with previously untreated acute myeloid leukemia who are not eligible for standard induction therapy.
Alecensa (alectinib, RG7853) is a small molecule designed to selectively target ALK (anaplastic lymphoma kinase) and to penetrate and stay in the central nervous system. Alectinib binds ALK, inhibiting downstream malignant pathways that contribute to tumorigenesis and disease progression. A phase II/III clinical trial is evaluating Alecensa for the treatment of non-squamous non-small cell lung cancer patients who are ALK+.
Crovalimab (RG6107) is a humanised complement inhibitor C5 monoclonal antibody discovered by Chugai using recycling antibody technology. By blocking the cleavage of C5 to C5a and C5b, it is expected to inhibit complement activation, which is the cause of a number of diseases. As the complement system is a key innate immune defense mechanism, we plan to study the potential of this antibody in a broader range of complement-mediated diseases. A phase I/II clinical trial is evaluating crovalimab for the treatment of paroxysmal nocturnal hemoglobinuria.
RG7835 is a conjugate of human IL-2 and IgG (fused IL-2 mutein). IgG–IL2 preferentially stimulates and expands T regulatory cells but not T effector cells. A phase I clinical trial is evaluating RG7835 for the treatment of autoimmune diseases.
ASO factor B (IONIS) is an antisense oligonucleotide that inhibits complement factor B gene expression by binding with factor B mRNA. ASO factor B is being studied for the treatment of IgA-nephropathy. A phase II clinical trial is evaluating ASO factor B for the treatment of IgA-nephropathy.
RG6149 (anti-ST2, AMG 282) is a fully human monoclonal antibody designed to inhibit binding of interleukin-33 (IL-33) to the ST2 receptor.
RG6149 (anti-ST2, AMG 282) is a fully human monoclonal antibody designed to inhibit binding of interleukin-33 (IL-33) to the ST2 receptor. A phase II clinical trial is evaluating RG6149 for the treatment of asthma.
Phase II study of pentraxin-2 (rhPTX-2; PRM-151) in myelofibrosis
Phase II study of pentraxin-2 (rhPTX-2; PRM-151) in idiopathic pulmonary fibrosis
RG7845 (GDC-0853) is a novel Bruton’s tyrosine kinase (BTK) inhibitor that helps block B cell proliferation and the resulting excessive immune response seen in autoimmune disorders. RG7845 binds to BTK in a novel way that is believed to increase its effectiveness. A phase II clinical trial is evaluating RG7845 as a potential therapeutic option in difficult-to-treat autoimmune diseases.
RG7880 (IL22-Fc, UTTR1147A) is a recombinant human protein with potential application across multiple inflammatory and metabolic diseases. A phase II clinical trial is evaluating RG7880 for the treatment of inflammatory diseases.
RG7880 (IL22-Fc, UTTR1147A) is a recombinant human protein with potential application across multiple inflammatory and metabolic diseases.
Actemra/RoACTEMRA (tocilizumab) is a humanised monoclonal antibody to the interleukin-6 receptor, inhibiting the activity of interleukin-6 and is being investigated in the treatment of Covid-19 pneumonia in combination with remdesivir.
Actemra/RoACTEMRA (tocilizumab) is a humanised monoclonal antibody to the interleukin-6 receptor, inhibiting the activity of interleukin-6 and is being investigated in the treatment of Covid-19 pneumonia.
Xolair (omalizumab, RG3648) is a monoclonal antibody that specifically targets the antibody IgE (immunoglobulin E). In nasal polyps (NP) IgE is increased in mucosal tissue and frequently in serum.
Crovalimab (RG6107) is a humanised complement inhibitor C5 monoclonal antibody discovered by Chugai using recycling antibody technology. By blocking the cleavage of C5 to C5a and C5b, it is expected to inhibit complement activation, which is the cause of a number of diseases. As the complement system is a key innate immune defense mechanism, we plan to study the potential of this antibody in a broader range of complement-mediated diseases.
Crovalimab (RG6107) is a humanised complement inhibitor C5 monoclonal antibody discovered by Chugai using recycling antibody technology. By blocking the cleavage of C5 to C5a and C5b, it is expected to inhibit complement activation, which is the cause of a number of diseases. As the complement system is a key innate immune defense mechanism, we plan to study the potential of this antibody in a broader range of complement-mediated diseases.
Obinutuzumab (RG7159, GA101) is the first glycoengineered, type II, humanised anti-CD20 monoclonal antibody. It has a distinct mode of action compared with other anti-CD20s, including MabThera/Rituxan, and was specifically designed to selectively target the CD20 protein on B cells and to bind with high affinity to the cell surface in a type II configuration.
Etrolizumab (RG7413) is a humanized IgG1 MAb targeting the beta 7 integrin subunit. It binds to two integrin receptors, alpha4beta7 and alphaEbeta7. These receptors are required for trafficking and retention in lymphocytes in the gastrointestinal tract and appear to play a role in inflammatory bowel diseases. Phase III clinical trials are evaluating etrolizumab for the treatment of Crohn's disease.
Xolair (omalizumab, RG3648) is a monoclonal antibody that specifically targets the antibody IgE (immunoglobulin E). In nasal polyps (NP) IgE is increased in mucosal tissue and frequently in serum. Two phase III clinical trial are evaluating Xolair for the treatment of chronic rhinosinusitis with nasal polyps.
Xolair (omalizumab, RG3648) is a monoclonal antibody that specifically targets the antibody IgE (immunoglobulin E). In nasal polyps (NP) IgE is increased in mucosal tissue and frequently in serum.
ASO factor B (IONIS) is an antisense oligonucleotide that inhibits complement factor B gene expression by binding with factor B mRNA. ASO factor B is being studied for the treatment of geographic atrophy. A phase II clinical trial is evaluating ASO factor B for the treatment of geographic atrophy.
Ranibizumab (RG6321), the active ingredient of Lucentis, is a monoclonal antibody fragment. It is designed to bind to and inhibit VEGF (vascular endothelial growth factor), a protein that is believed to play a critical role in the formation of new blood vessels (angiogenesis) and the hyperpermeability (leakiness) of the vessels. A phase III clinical trial is evaluating ranibizumab delivered via the port delivery system implant for the treatment of patients with diabetic macular edema (DME).
Ranibizumab, the active ingredient of Lucentis, is a monoclonal antibody fragment. It is designed to bind to and inhibit VEGF (vascular endothelial growth factor), a protein that is believed to play a critical role in the formation of new blood vessels (angiogenesis) and the hyperpermeability (leakiness) of the vessels. A phase III clinical trial is evaluating ranibizumab delivered via the ranibizumab port delivery system implant for the treatment of patients with subfoveal neovascular age-related macular degeneration. The primary outcome measure of the trial is the time until a patient first requires a refill of the implant.
Ranibizumab, the active ingredient of Lucentis, is a monoclonal antibody fragment. It is designed to bind to and inhibit VEGF (vascular endothelial growth factor), a protein that is believed to play a critical role in the formation of new blood vessels (angiogenesis) and the hyperpermeability (leakiness) of the vessels. A phase III clinical trial is evaluating ranibizumab delivered via the ranibizumab port delivery system implant for the treatment of patients with subfoveal neovascular age-related macular degeneration. The primary outcome measure of the trial is the time until a patient first requires a refill of the implant.
Faricimab (RG7716) is a bispecific antibody developed with CrossMab technology to tightly bind VEGF-A on one arm and angiopoietin (Ang)-2 on the other arm. Two phase III clinical trials are evaluating faricimab for the treatment of diabetic macular edema.
Faricimab (RG7716) is a bispecific antibody developed with CrossMab technology to tightly bind VEGF-A on one arm and angiopoietin (Ang)-2 on the other arm. Two phase III clinical trials are evaluating faricimab for the treatment of neovascular age related macular degeneration.
RG6346 (DCR-HBVS) is a liver-targeted siRNA that employs RNA interference (RNAi) for selective knock-down of Hepatitis B virus gene expression in infected hepatocytes, inhibiting the production of viral factors required for viral replication. RG6346 leverages Dicerna Pharmaceuticals, Inc.’s proprietary GalXC™ RNAi technology. RG6346 is in a phase I clinical trial for the treatment of non-cirrhotic chronic HBV infection.
TLR7 agonist (RG7854) is an oral, small molecule immuno-modulator activating the TLR (toll-like receptor) 7 and to a weaker extent TLR8. It is developed as best-in-disease for finite chronic hepatitis B combination therapy. A phase I clinical trial is evaluating RG7854 for the treatment of chronic hepatitis B infection.
CpAM (RG7907) is an orally administered small molecule, class I hepatitis B virus (HBV) core protein allosteric modulator, that disrupts HBV nucleocapsids assembly and induces the depletion of functional core proteins, thereby effectively inhibiting HBV replication. A phase I clinical trial is evaluating RG7907 for the treatment of chronic hepatitis B infection.
TLR7 agonist (RG7854) in combination with RG7907 CpAM (2)
Xofluza (baloxavir marboxil, RG6152) is an oral cap-dependent endonuclease inhibitor with broad and potent antiviral activity against seasonal influenza A and B viruses. Xofluza is being evaluated in a phase III clinical trial for the treatment of pediatric patients with the flu.
Xofluza (baloxavir marboxil, RG6152) is an oral cap-dependent endonuclease inhibitor with broad and potent antiviral activity against seasonal influenza A and B viruses.
Xofluza (baloxavir marboxil, RG6152) is an oral cap-dependent endonuclease inhibitor with broad and potent antiviral activity against seasonal influenza A and B viruses. Xofluza is being evaluated in a phase III clinical trial for the treatment of patients hospitalized with the flu.
Xofluza (baloxavir marboxil, RG6152) is an oral cap-dependent endonuclease inhibitor with broad and potent antiviral activity against seasonal influenza A and B viruses. Xofluza is being investigated in a Phase III clinical trial in people with the flu who are at high risk of complications
Xofluza (baloxavir marboxil, RG6152) is an oral cap-dependent endonuclease inhibitor with broad and potent antiviral activity against seasonal influenza A and B viruses. Xofluza is being evaluated in a phase III clinical trial of post exposure prophylaxis.
Xofluza (baloxavir marboxil, RG6152) is an oral cap-dependent endonuclease inhibitor with broad and potent antiviral activity against seasonal influenza A and B viruses. Xofluza is being evaluated in a phase III clinical trial for the treatment of people with flu but otherwise healthy.
Xofluza (baloxavir marboxil, RG6152) is an oral cap-dependent endonuclease inhibitor with broad and potent antiviral activity against seasonal influenza A and B viruses. Xofluza is being evaluated in a phase III clinical trial for the treatment of pediatric patients with the flu.
UBE3A-LNA is a locked nucleic acid developed for the treatment of Angelman syndrome which is caused by a lack of UBE3A expression in the brain. The LNA targets the paternal antisense RNA and enables the expression of UB3A in neurons.
Brain shuttle technology to transfer gantenerumab across the blood brain barrier and increase antibody concentrations in the brain
RG7816 is a small molecule highly selective positive allosteric modulator of the GABAA α5 receptor, which is expressed in key brain regions for autism spectrum disorder. Two phase I clinical trial is evaluating RG7816 for the treatment of patients with autism spectrum disorder.
RG6100 (Anti Tau) is an investigational medicine being evaluated as a potential treatment for Alzheimer’s disease. A phase II clinical trial is evaluating RG6100 for the treatment of patients with Alzheimer's disease.
Phase II gene therapy in Duchenne muscular dystrophy (DMD)
Crenezumab (RG7412) is a humanized monoclonal antibody, which binds to amyloid beta (Abeta). Abeta is the main constituent of amyloid plaque in the brains of patients with Alzheimer's disease and is proposed to be causative in the development of the disease. A phase II clinical trial is evaluating crenezumab in healthy individuals with a history of familial Alzheimer’s disease.
Prasinezumab (RG7935) is a monoclonal antibody targeting alpha-synuclein, a protein that may misfold and be involved in the pathogenesis of Parkinson's disease. It has been tested in preclinical models of synuclein-related disease and has shown a reduction of neurodegeneration. A phase II clinical trial is evaluating prasinezumab for the treatment of patients with Parkinson's disease.
Gantenerumab (RG1450) is a fully human monoclonal antibody that binds and neutralises disease-relevant aggregated forms of amyloid-beta: those that accumulate as plaques in the brain and those which interfere with brain-cell functioning. A phase III clinical trial is evaluating gantenerumab for the treatment of Alzheimer's disease.
tominersen (ASO-HTT, RG6042) is an antisense drug in development for the treatment of Huntington's Disease. tominersen is designed to reduce the production of all forms of the huntingtin (HTT) protein, which in its mutated variant (mHTT) is responsible for Huntington's Disease. Multiple clinical trials are evaluating tominersen for the treatment of patients with Huntington's Disease.
NXT007 is an optimized anti-FIXa/FX bispecific monoclonal antibody. NXT007 has an enhanced hemostatic activity and improved pharmacokinetics by antibody engineering technologies. The bispecific antibody is in phase I/II clinical study for healthy volunteers and hemophilia A.
Emicizumab (RG6013, ACE910) is a bispecific antibody that mimics coagulation factor VIII, an essential blood clotting protein. It is being investigated as a therapy for people with mild ot moderate hemophilia A, a congenital bleeding disorder that is caused by deficiency or dysfunction of coagulation factor VIII.
Sorry, the filter or keyword combination yields no results.
Try removing some filters or search for another keyword.
WW - Worldwide.
EU - European Union.
US - United States.
* - Achieve commercial readiness, dependent on Pharma label and approval.